SANGAMO THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
SANGAMO THERAPEUTICS, INC. (SGMOQ) reported Net Income (Loss) Available to Common Stockholders, Basic of -$31.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-05-14
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$31.00M.
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$34.93M, a 472.19% decline year-over-year.
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$30.60M.
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was $9.38M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month |
|---|---|---|---|
| 2026-03-31 | -$31.00M 10-Q · filed 2026-05-14 | ||
| 2025-09-30 | -$34.93M 10-Q · filed 2025-11-06 | -$85.51M 10-Q · filed 2025-11-06 | |
| 2025-03-31 | -$30.60M 10-Q · filed 2026-05-14 | ||
| 2024-09-30 | $9.38M 10-Q · filed 2025-11-06 | -$74.55M 10-Q · filed 2025-11-06 | |
| 2023-09-30 | -$104.16M 10-Q · filed 2024-11-12 | -$197.54M 10-Q · filed 2024-11-12 | |
| 2022-09-30 | -$53.16M 10-Q · filed 2022-11-03 | -$96.33M derived: sum of 2 quarters · filed 2022-11-03 | -$140.31M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$43.17M 10-Q · filed 2022-08-04 | -$87.15M 10-Q · filed 2022-08-04 | |
| 2021-09-30 | -$47.69M 10-Q · filed 2022-11-03 | -$94.86M derived: sum of 2 quarters · filed 2022-11-03 | -$140.79M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$47.17M 10-Q · filed 2022-08-04 | -$93.10M 10-Q · filed 2022-08-04 |